Abstract：
Increasing knowledge of the processes leading to heart failure (HF) has allowed significant developments in therapies for HF over the past few decades. Despite the evolution of HF treatment, it still places a large burden on patients and health care systems across the world.We used clinicaltrials.gov to gather information about clinical trials as of August 2023 studying pharmacotherapy for HF. We included interventional trials that were \"active, not recruiting\", \"recruiting\", or looking for participants but \"not yet recruiting\". In total, 119 studies met our criteria of ongoing clinical trials studying novel as well as currently approved HF pharmacotherapies. The major interventions were novel medications/already approved medications for other diseases 29 % (34 trials), sodium-glucose co-transporter inhibitors 21 % (25 trials), angiotensin receptor blocker-neprilysin inhibitors 10 % (12 trials), diuretics 14 % (17 trials) and mineralocorticoid receptor antagonists 5 % (6 trials). Ongoing research will aid in reducing the impact of HF and we summarize clinical trials leading the way to better HF treatment in this review.
摘要：
在过去的几十年中，对导致心力衰竭（HF）的过程的了解不断增加，使HF的治疗方法得到了重大发展。尽管HF治疗的发展，它仍然给世界各地的患者和医疗保健系统带来巨大负担。我们使用clinicaltrials.gov收集截至2023年8月研究HF药物治疗的临床试验信息。我们包括了积极的介入试验，不招募\“，“招募”，或寻找参与者，但“尚未招募”。总的来说,119项研究符合我们正在进行的临床试验标准，研究新的以及目前批准的HF药物疗法。主要干预措施是新药物/已批准的其他疾病药物29%（34项试验），钠-葡萄糖协同转运蛋白抑制剂21%（25项试验），血管紧张素受体阻滞剂-脑啡肽抑制剂10％（12项试验），利尿剂14%(17项试验)和盐皮质激素受体拮抗剂5%(6项试验)。正在进行的研究将有助于减少HF的影响，我们在这篇综述中总结了导致更好的HF治疗方法的临床试验。
